Amber Therapeutics Announces Successful First-in-human Implants of Amber-UI: An Intelligent, Closed-loop Bioelectrical Therapy for Urge and Mixed Urinary Incontinence

Amber Therapeutics (‘Amber’ or the ‘Company’), a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces that the first participants have been implanted with Amber-UI, the Company’s proprietary therapy for urge and mixed urinary incontinence (UI).

Amber-UI is the first fully implantable closed-loop bioelectrical therapy in clinical development for UI, which is made possible by being able to access and target the pudendal nerve – the nerve that directly controls continence – through a novel, minimally invasive surgical procedure.

Leveraging its expertise in closed-loop neuromodulation concepts, Amber’s multi-modal therapy can both directly regulate the urge to void the bladder (urge incontinence or overactive bladder) and augment resistance to urine leakage caused by activities such as coughing or lifting (stress incontinence), allowing for restoration of normal bladder function.

To explore the clinical potential of Amber-UI, the Company initiated its ground-breaking AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study in late 2022 ( identifier: NCT05241379). AURA-2 is designed to evaluate the safety and pilot efficacy of Amber-UI in 15 women. The study is being conducted at the University Hospital Antwerp (Belgium) by Stefan De Wachter, Professor of Urology, a leading expert in pelvic floor disorders and a co-founder of Amber.

To date, three participants have been safely implanted with the Amber-UI system with the adaptive algorithm activated and running continuously in an at-home setting. The remaining participants will be enrolled during the first half of 2023. Early indications confirming the feasibility of the surgical procedure and therapy are very promising.

The study is expected to conclude towards the end of 2023, with learnings used to improve and optimise the Amber-UI therapy in preparation for a pivotal trial.

Amber received seed funding for its development work to advance Amber-UI into the AURA-2 clinical study from Oxford Science Enterprises, 8VC and a UKRI Biomedical Catalyst grant.

For the AURA-2 study, Amber has partnered with Bioinduction Limited (Bristol, UK) for use of its Picostim DyNeuMo Research Platform, developed in collaboration with the University of Oxford, which leverages Bioinduction’s core Picostim Deep Brain Stimulation (DBS) System.

Aidan Crawley, CEO of Amber commented: “Reaching this first-in-human milestone in under two years demonstrates our ability to rapidly prototype new bioelectrical therapy concepts. But what is most exciting is the potential for our UI therapy to have a radical impact on clinical outcomes not only in patients with urge UI, but also for the first time in the many more patients with mixed UI for whom no single therapy is currently available.”

Stefan De Wachter, Professor of Urology at Antwerp University and leading investigator for the AURA-2 study added: “Most of the current available implanted therapies for incontinence are static (tapes, slings) or can only influence the bladder indirectly (such as sacral or tibial nerve stimulation). With Amber-UI, we stimulate the pudendal nerve, the natural pathway of continence control, and can reinforce the existing physiologic reflexes when it is needed. With our Amber-UI adaptive therapy, we finally have the potential to control both forms of incontinence: relaxing the bladder to treat urge and closing the sphincter to treat stress incontinence.”

Tim Denison, Chief Scientific Officer of Amber and RAEng Chair in Emerging Technology, University of Oxford, said: “Modern bioelectronic systems have the unique capability to measure physiological signals and adjust stimulation in real-time. In partnership with clinicians, we can create novel adaptive reflex-like algorithms for exploring new therapies.”

Charles Knowles, Chief Medical Officer of Amber and Professor of Surgery at Queen Mary University of London, said “Urinary incontinence is one of the most common medical problems in humans. It causes misery for millions of women and men worldwide. Amber-UI represents the first advanced therapy directed to both urge and mixed urinary incontinence and, if our study is successful, will be a major step forward in a field that has seen little real innovation for over a quarter of a century.”

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy